S-1-based combination therapy vs S-1 monotherapy in advanced gastric cancer: A meta-analysis

Table 5 Outcome of toxicity meta-analysis comparing S-1-based combination therapy vs S-1 monotherapy as first-line treatment in advanced gastric cancer

Toxicity	S-1-based therapy	S-1 monotherapy	OR (95%CI)	Pvalue	Heterogeneity
Grade 3-4	n/N	n/N			Pvalue	I2
Leucopenia	44/392	12/398	4.06 (2.11-7.81)	< 0.01	0.728	0.00%
Neutropenia	127/392	43/398	3.94 (2.70-5.77)	< 0.01	0.334	11.90%
Anaemia	77/392	30/398	5.96 (3.03-11.73)	< 0.01	0.423	0.00%
Thrombocytopenia	11/392	10/398	0.33 (0.10-1.12)	0.076	0.900	0.00%
Anorexia	91/392	47/398	2.40 (0.79-7.28)	0.122	0.000	83.40%
Nausea	41/392	16/398	2.80 (0.92-8.55)	0.070	0.048	62.00%
Fatigue	26/392	20/398	1.35 (0.74-2.46)	0.336	0.506	0.00%
Vomiting	15/392	9/398	1.71 (0.74-3.96)	0.207	0.707	0.00%
Diarrhea	35/392	16/398	2.41 (1.31-4.44)	< 0.01	0.614	0.00%
Stomatitis	7/392	2/398	2.52 (0.71-8.79)	0.151	0.994	0.00%

S-1-based: S-1-based combination therapy.